PLC Systems Inc., a Massachusetts based medical technology company, announced today that the U.S. Patent & Trademark Office had issued Notices of Allowance for two of the company’s patent applications associated with its innovative RenalGuard® technology. The company expects U.S. patents to be issued within several months. The company is expected to continue work with the U.S. Patent Office, as well as patent organizations in other countries, to advance more patent applications relating to RenalGuard, including pending patents for the RenalGuard product and associated fluid balancing techniques and systems.

RenalGuard Therapy® is designed to reduce the toxic effects of contrast media on kidneys for patients undergoing imaging procedures. Contrast agents are the various chemical substances introduced into the body to facilitate radiographic imaging of internal structures. RenalGuard Therapy is designed to reduce the toxic effects that contrast media can have on the kidneys, which may lead to a reduction in the incidence of Contrast-Induced Nephropathy (a form or acute renal failure) in at-risk patients.

The therapy is based on existing published literature and initial pre-clinical work performed by PLC Medical Systems, which supports the theory that creating and maintaining a high urine output through the kidneys allows the body to rapidly eliminate contrast, reducing its toxic effects. It involves use of a diuretic to induce high urine output, together with a system designed to measure output and to replace it with sterile saline to guard against over or under hydration.

PLC president and CEO, Mark R. Tauscher, stated, “We are truly delighted with the positive response from the U.S. Patent Office about our proprietary RenalGuard technology, which is designed to prevent Contrast Induced Nephropathy (CIN). This is a critical milestone for our company and for RenalGuard. We will to continue to build our patent position to enhance the value of our RenalGuard technology and method of CIN prevention. Combined with the positive results we are seeing from investigator-sponsored clinical trials of RenalGuard in Italy, this achievement provides us with heightened confidence in our future. We look forward to continuing our discussions with potential strategic and financial partners, armed with this important validation.”